Evaxion Biotech A/S
NASDAQ:EVAX

Watchlist Manager
Evaxion Biotech A/S Logo
Evaxion Biotech A/S
NASDAQ:EVAX
Watchlist
Price: 5.78 USD -6.92% Market Closed
Market Cap: 36.5m USD

Net Margin
Evaxion Biotech A/S

-70.9%
Current
-3 780%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-70.9%
=
Net Income
-5.4m
/
Revenue
7.7m

Net Margin Across Competitors

No Stocks Found

Evaxion Biotech A/S
Glance View

Market Cap
36.5m USD
Industry
Biotechnology

Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

EVAX Intrinsic Value
3.5 USD
Overvaluation 39%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-70.9%
=
Net Income
-5.4m
/
Revenue
7.7m
What is the Net Margin of Evaxion Biotech A/S?

Based on Evaxion Biotech A/S's most recent financial statements, the company has Net Margin of -70.9%.

Back to Top